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Introduction
Antimony and arsenic are elements that
have a long history of use as poisons,
therapeutic agents, or cosmetics. For over
a century, compounds containing penta-
valent antimony (antimonials) have
formed the basis of treatment of the
leishmaniases worldwide. Antimonial
preparations remain first-line drugs for
visceral leishmaniasis in Sub-Saharan
Africa and Brazil [1], but in the hyperen-
demic state of Bihar, India, the cure rate of
antimonial compounds has declined over
the past 30 years from over 85% to less
than 50% (Figure 1) [2] and resistance in
parasites has been demonstrated [3]. This
marked decrease in efficacy has been
attributed to long-term, widespread misuse
of antimonials, with patients undergoing
inappropriate treatment courses often
administered by the largely unregulated
Indian private health care system [4,5].
Here we propose an additional hypothesis
to explain the substantially lower efficacy
of antimony in Bihar compared to other
regions in the world.
Since the 1970s, millions of inhabitants
of Asia have been chronically exposed to
naturally occurring arsenic on a daily basis
through the large-scale insertion of multi-
ple shallow tubewells which were original-
ly installed for provision of clean and safe
drinking water [6]. Antimony and arsenic
are metalloids belonging to Group 15 of
the periodic table that share many struc-
tural and chemical properties [7]. Anti-
mony resistance in Leishmania parasites can
be induced experimentally by exposure to
stepwise increasing concentrations of sub-
lethal concentrations of trivalent arsenite
in culture [8]. If an individual who is
chronically exposed to arsenic is infected
with Leishmania, the parasites would be
exposed to arsenic due to its presence
within organs of the lymphoreticular
system [9]. This could lead to the
development of an arsenic-resistant Leish-
mania strain that would be cross-resistant
to antimonial therapy. This viewpoint
article will expand on, and discuss the
evidence for, the possible contribution of
arsenic to decreased antimonial efficacy in
Bihar.
Visceral Leishmaniasis
The Leishmaniases are a group of
diseases caused by infection with the
protozoan parasite Leishmania, transmitted
by the sandfly. The most serious form of
the disease is visceral leishmaniasis, which
results from infection with Leishmania
donovani and Leishmania infantum. The
amastigote form replicates in macrophages
of the liver, spleen, and bone marrow,
causing persistent fever, hepatosplenomeg-
aly, weight loss, and pancytopenia. If
untreated it is eventually fatal [10] and is
thought to account for 41,000 deaths per
year [1].
Approximately 60% of the worldwide
incidence of visceral leishmaniasis is in the
Indian subcontinent [11], where it has an
anthroponotic transmission which follows
a cluster pattern. Ninety percent of India’s
disease burden is thought to occur in Bihar
[12], and in 2009, the incidence was
estimated at 22 per 10,000 of the popula-
tion [13]. Supported by the World Health
Organisation, the governments of India,
Nepal, and Bangladesh are currently
implementing an elimination programme
that aims to reduce the incidence of the
disease to less than 1 per 10,000 by 2015
[13].
Resistance and Epidemiology
Visceral leishmaniasis was almost elim-
inated in India in the 1950s and 1960s as a
secondary consequence of the National
Malaria Eradication programme. After the
programme’s termination the sandfly vec-
tor population increased, resulting in a
resurgence of visceral leishmaniasis reach-
ing epidemic proportions in the late 1970s
[14]. Primary unresponsiveness to antimo-
nials became evident during this epidemic
when physicians found the prior standard
6-day antimonial regime to be ‘‘grossly
inadequate’’ [15]. As a result, a 20-day
regime at 10 mg/kg was introduced which
was further increased in subsequent years
up to 20 mg/kg for 30 days to try to
reduce the increasingly high rate of relapse
[16]. Despite this, cure rates with antimo-
nial treatment continued to fall [2].
Subsequently, new, effective therapies,
such as oral miltefosine and intravenous
amphotericin B deoxycholate, have been
incorporated into routine clinical practice
and now form the treatment backbone of
the visceral leishmaniasis elimination pro-
gramme [11].
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The emergence of decreased antimonial
efficacy within the epidemic occurred in
the years directly following the large-scale
insertion of shallow tubewells across Asia
in the early 1970s. The natural occurrence
of high levels of arsenic in the groundwater
accessed by many of these tubewells was
only discovered in Bihar in 2002 [17],
although it is believed to have been
present since the tubewells were inserted
[6]. This late finding came despite Bihar’s
close geographic proximity to West Bengal
and Bangladesh, where the occurrence of
mass arsenic poisoning was identified in
the 1980s and 1990s, respectively [6]. By
2007 UNICEF had tested 66,623 tube-
wells in Bihar and found 28.9% had
arsenic levels greater than the WHO
standard of 10 mg/L, affecting at least
7.2 million of the population [6].
The Indian subcontinent is the only
place worldwide where endemic visceral
leishmaniasis and significant arsenic con-
tamination of the groundwater co-exist
[6], and it is from Bihar and Nepal that
the highest rates of antimonial treatment
failures are found [4,18]. In the map of
Bihar in Figure 2, the available informa-
tion from journals, websites, and published
databases on the incidence of visceral
leishmaniasis, antimonial resistance, and
arsenic contamination of the groundwater
has been collated. This epidemiological
data must be interpreted in the context of
an estimated 73%–90% under-reporting
of visceral leishmaniasis [19] and the
incomplete analysis of tubewell water
throughout Bihar. However, it does dem-
onstrate 10 endemic VL districts where
part of the population’s consumption of
water from arsenic contaminated tube-
wells could have resulted in the induction
of antimonial resistance of Leishmania
parasites through arsenic exposure via
their human host. Our hypothesis has
parallels with the subtherapeutic exposure
of South American, South East Asian, and
African populations to chloroquine
through medicated salt in the 1950s and
1960s, which is thought to have contrib-
uted to the spread of chloroquine resistant
malaria [20].
In the northern areas of Bihar there is
less reported arsenic contamination of
groundwater [6], but antimonial resistance
is still present at high levels. Worker
migration between districts is common in
Bihar [21] and dissemination of resistant
strains from areas of high level arsenic
exposure along the Ganges to the north
through clusters of dense visceral leish-
maniasis incidence would account for this
epidemiological pattern. This is supported
by known high rates of transmission [19],
demonstrable superior fitness of clinical
resistant strains [22], and long-term
stability of resistant laboratory strains
passaged in the absence of metalloid
pressure [23,24].
In neighbouring Bangladesh, where
minimal antimonial resistance has been
reported, high-level arsenic contamination
is mainly in the south of the country [6],
whereas visceral leishmaniasis is mainly
found in the north [25]. In other endemic
countries such as Sudan and Brazil, where
there is no reported arsenic contamination
of the groundwater, efficacy rates are
greater than 95% [1]. In Sudan and Brazil
prevalent issues such as intermittent poor
drug availability, low treatment compli-
ance, and civil unrest could also have led
to inadequate or interrupted treatment
courses. The current thinking that drug
misuse is solely responsible for the dra-
matic development of resistance in Bihar
does not account for the presence of these
same issues in countries where antimonials
remain an effective treatment.
Resistance and Biochemistry
Chronic arsenic exposure through
drinking water is associated with an
increased mortality rate [26], particularly
from cancer, cardiovascular diseases, and
infections [27]. Arsenic exists in ground-
water as arsenate (AsV) or arsenite (AsIII),
which, following ingestion, is metabolised
in the liver via a series of reduction and
subsequent oxidative methylation steps to
methylarsonic acid and dimethylarsinic
acid. The majority is excreted in those
forms over subsequent days in the urine
[28], but a small proportion accumulates
in the skin, hair, and nails [28] mainly as
AsIII and AsV [29] and, significantly for
this hypothesis, in the liver [9,30]. There
are no data currently available in chron-
ically arsenic exposed humans on arsenic
levels in the spleen or bone marrow, the
other organs where parasites reside in
visceral leishmaniasis.
In the livers of laboratory animals, total
arsenic levels (both methylated and inor-
ganic forms) have been shown to be
related to dose and duration of exposure.
BALB/c mice orally dosed with 150 mg of
arsenite for 6 out of 7 days a week for a
year show an almost 10-fold increase in
total hepatic arsenic from ,0.5 mg/kg to
,4.5 mg/kg [30]. Comparable total he-
patic arsenic contents, ranging from un-
detectable levels up to 6 mg/kg, were
found in liver biopsies performed on a
small cohort of 13 hepatomegalic patients
Figure 1. Results of consecutive clinical studies of antimonials at 20 mg/kg dosing in
Bihar, India. Graph drawn from data presented in tabular form in a systematic review of clinical
trials done in India between 1980 and 2004 [2]. Doses received are indicated in the figure key.
Linear regression correlation coefficient = 20.831.
doi:10.1371/journal.pntd.0001227.g001
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from West Bengal, who had been envi-
ronmentally exposed to arsenic levels of
220 to 2,000 mg/L for 1 to 20 years [9].
Should arsenite levels in spleen, bone
marrow, and liver macrophages be freely
bioavailable and similar to total hepatic
arsenic content, then it is theoretically
possible that arsenite could kill Leishmania
parasites and thus have a protective effect
against infection. More likely, however, is
that arsenic levels within macrophages of
chronically arsenic exposed patients are
sublethal, thus creating an environment
where resistance can develop. Developing
arsenical resistance through selective envi-
ronmental exposure is a well-researched
and established mechanism in microor-
ganisms [31]. Since the incubation period
of visceral leishmaniasis ranges from weeks
to months [10], parasites could develop
tolerance to arsenite by evolving resistance
mechanisms that would also be effec-
tive against antimonial compounds when
administered as treatment. Although there
are no direct reports of uptake of arsenic
into macrophages, it is plausible to assume
that this does occur because pentavalent
antimony is known to be taken up by
macrophages [32] and both trivalent
arsenic and antimony have be shown to
be taken up, via aquaglyceroporin 9, by
undifferentiated human leukaemia cells
[33].
There has been extensive research on
the mechanisms by which Leishmania
parasites acquire resistance to antimonial
preparations [4]. This research initially
involved generation of antimonial-resistant
strains through stepwise exposure of Leish-
mania parasites to arsenite in vitro in order
to study an arsenite-thiol conjugate trans-
porter PgpA [34], which was subsequently
found to be an important vacuolar seques-
tration mechanism involved in Leishmania
antimonial resistance [35]. Both arsenite
and antimony have since been used to
select resistance and many common
mechanisms have been demonstrated [4]
that have subsequently been identified in
antimonial-resistant clinical isolates [36,37].
The full mechanism of action of anti-
mony itself is incompletely understood. It
is known to be active in its trivalent form
[38], but is administered as a prodrug in
pentavalent form and reduced either in
the macrophage, in the amastigote, or
both [4]. In a sensitive parasite lineage
trivalent forms of arsenic and antimony
accumulate within the parasite, but this
accumulation is found to be reduced in
resistant strains [39]. Both antimony and
arsenic in their molecular form as anti-
monite (Sb(OH)3) and arsenite (As(OH)3)
react with sulphydryl groups and are
thought to be leishmanicidal through
depletion and interference with the para-
site’s unique thiol system [38,40], which is
dependent on the dithiol trypanothione.
This system is responsible for maintaining
the parasite’s redox balance and thus its
ability to defend against oxidative stress. In
both laboratory and clinical-resistant par-
asite isolates an increase in protective
thiols [39] and overexpression of associat-
ed enzymes has been reported [41].
Figure 2. Map of Bihar showing district distribution of visceral leishmaniasis endemicity, antimonial resistance, and arsenic
contamination of the groundwater. The map is based on published data [4,6,44–46] with additional data from http://www.indiawaterportal.org/
node/10925 and http://www.soesju.org/arsenic/groundwater_bihar.htm, both last accessed 12/20/2010. Data for Muzaffarpur are from personal
correspondence with Dr. Ashok Ghosh, A.N. College, Patna.
doi:10.1371/journal.pntd.0001227.g002
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Further Investigation
Establishing whether arsenic exposure
could have contributed to antimonial
resistance is a process that will require
the integration of epidemiological, clinical,
biological, and analytical chemistry data.
Due to high levels of treatment failure
antimonial compounds are no longer the
first-line treatment in Bihar. Thus, assess-
ment of resistance relies on retrospective
clinical data or upon the analysis of clinical
parasite isolates using in vitro assays. The
latter can be an unreliable indication of
clinical response [42] and produce vari-
able results depending on the methods
used [43]. Furthermore, if resistance is
identified in a Leishmania clinical isolate it is
not currently possible to determine wheth-
er this is due to prior arsenic or antimonial
exposure via the patient or whether this
was transmitted from a prior human host.
We hope to be able to demonstrate proof
of concept in the laboratory using in vitro
systems and through exposing L. donovani
infected laboratory animals to environ-
mentally relevant levels of arsenic in their
drinking water. This laboratory work will
help to guide future clinical and epidemi-
ological research.
Conclusion
Biochemical, historical, and geographi-
cal data indicate a significant link between
arsenic contamination of the groundwater
and the development of high levels of
resistance to antimonial compounds found
in the treatment of visceral leishmaniasis
in Bihar. As antimonials are still being
used widely elsewhere in the world,
continued efforts into gaining full under-
standing of the reduced efficacy of this
drug in Bihar will be beneficial in guiding
future drug combination policy and treat-
ment options.
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